Menu
Our focus
Rosetta is a venture capital firm focused on the life science and medical device sectors. We invest through direct secondary transactions to provide flexible liquidity solutions to investors or corporations
Secondary direct transactions provide investors with the opportunity to liquidate existing portfolio holdings before an exit is achieved to release capital for alternative uses. Rosetta is experienced in completing transactions with a variety of sellers, optimizing the deal structure depending on the unique situation and requirements of the seller.
Rosetta is experienced in completing secondary transactions with a variety of sellers, optimizing the deal structure depending on the unique situation and requirements of the seller.
Rosetta will continue to support companies they invest in through follow-on financings and strategic engagement with company boards, management, and co-investors to guide the company through value inflection points.
Rosetta offering for investors
Secondary direct transactions provide an investor the opportunity to liquidate existing portfolio holdings before an exit is achieved and so release capital for alternative uses. Rosetta is experienced in completing transactions with a variety of sellers, optimizing the deal structure depending on the unique situation and requirements of the seller.
Rosetta offering for portfolio companies
Rosetta will continue to support companies they invest in through follow-on financings and strategic engagement with company Boards, management, and co-investors to guide the company through value inflection points.
Counterparties that seek liquiduity options through secondary transactions
Financial investors (e.g. venture capital or other private equity groups)
Academic institutions
Pension funds
Corporate venture capital groups
Rosetta has completed secondary transactions with all counterparties above.
Find out more
About us
We are a specialist UK-based life science venture capital firm that invests globally to build leading healthcare companies and breakthrough technologies that can deliver benefits to human lives. We invest through direct secondary transactions to provide flexible liquidity solutions to investors or corporations
Case studies
We have an experienced investment team that has a long history of completing secondary transactions with European and North American healthcare investors to acquire equity positions in portfolio companies.
